Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Afrezza Review Shows Need For Patient-Driven Endpoints In Diabetes

Apr 07 2014

• By Sue Sutter

Related Content

FDA Sets Up Afrezza Panel To Split Between Type 1 And 2 Diabetes

Mar 28 2014

Fibromyalgia Patient Meeting Shines Light On Lesser Known Symptoms

Mar 31 2014

Degludec Review Could Lead To New CV Safety Requirements For Insulins

Nov 12 2012

Insulin Degludec’s CV Risks Can Be Studied Post-Approval, Cmte. Says

Nov 08 2012

MannKind Shares Game Plan For Tackling Afrezza's Complete Response

Jan 19 2011

Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec

Feb 11 2013

Related Companies

MannKind Corporation

Novo Nordisk A/S

Pfizer Inc.

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window